CatalYm Appoints Peter Garcia as Chief Financial Officer
CatalYm Appoints Peter Garcia as Chief Financial Officer Munich, Germany and...
Read MoreCatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors...
Read MoreCatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...
Read MoreCatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination...
Read MoreCatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read MoreCatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in...
Read MoreCatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase...
Read MoreCatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read MoreCatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial...
Read MoreCatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development
CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development Experienced...
Read MoreCatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug...
Read MoreCatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical...
Read MoreCatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to...
Read MoreCatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD...
Read MoreCatalYm Announces Leadership Change
CatalYm Announces Leadership Change Munich, Germany, October 11, 2024 – CatalYm...
Read MoreCatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development...
Read MoreCatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily...
Read MoreCatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting
CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing...
Read MoreCatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors...
Read MoreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and...
Read MoreCatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...
Read MoreCatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination...
Read MoreCatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy...
Read MoreCatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...
Read MoreCatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...
Read MoreCatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...
Read MoreCatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in...
Read MoreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate...
Read MoreCatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...
Read MoreCatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...
Read MoreCatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15...
Read MoreCatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...
Read MoreCatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...
Read MoreCatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...
Read MoreCatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...
Read MoreCatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...
Read MoreCatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...
Read MoreCatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...
Read MoreCatalYm Announces Key Management and Board Changes
CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...
Read MoreCatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...
Read MoreCatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...
Read MoreCatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020
CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of...
Read More